Juthamas Sukbuntherng
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, PI3K/AKT/mTOR signaling in cancer, Monoclonal and Polyclonal Antibodies Research, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia(2013)2,236 cited
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.(2003)
- → Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies(2012)1,110 cited
- → Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL(2017)141 cited
- → Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men(2014)137 cited
- Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.(2003)
- → Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling(2016)109 cited
- → SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity(2006)103 cited
- → Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants(2015)98 cited
- → Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth(2016)93 cited